Jennifer I. Smart

578 total citations
28 papers, 366 citations indexed

About

Jennifer I. Smart is a scholar working on Infectious Diseases, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, Jennifer I. Smart has authored 28 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Infectious Diseases, 11 papers in Epidemiology and 11 papers in Clinical Biochemistry. Recurrent topics in Jennifer I. Smart's work include Antimicrobial Resistance in Staphylococcus (18 papers), Bacterial Identification and Susceptibility Testing (11 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Jennifer I. Smart is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (18 papers), Bacterial Identification and Susceptibility Testing (11 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Jennifer I. Smart collaborates with scholars based in United States, Switzerland and Argentina. Jennifer I. Smart's co-authors include Kamal Hamed, Rodrigo E. Mendes, Robert K. Flamm, Hélio S. Sader, Leonard R Duncan, Michael A. Pfaller, James B. Kaper, Vanessa Sperandio, Anne Santerre Henriksen and Nancy E. Freitag and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Journal of Virology.

In The Last Decade

Jennifer I. Smart

26 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer I. Smart United States	11	185	112	102	78	76	28	366
Falah Hasan Obayes Al-Khikani Iraq	13	156 0.8×	42 0.4×	208 2.0×	45 0.6×	82 1.1×	73	490
Noe Reyes United States	6	227 1.2×	142 1.3×	99 1.0×	99 1.3×	74 1.0×	7	335
Amy A. Watters United States	9	219 1.2×	58 0.5×	77 0.8×	109 1.4×	97 1.3×	12	336
Monica Borgonovi Italy	10	169 0.9×	181 1.6×	116 1.1×	63 0.8×	116 1.5×	19	423
David Styers United States	6	236 1.3×	45 0.4×	92 0.9×	141 1.8×	57 0.8×	8	460
J.F. Lemeland France	10	128 0.7×	54 0.5×	106 1.0×	93 1.2×	76 1.0×	26	350
Ianick Souto Martins Brazil	12	38 0.2×	82 0.7×	118 1.2×	62 0.8×	224 2.9×	29	385
Elizabeth A. Holmes United States	12	124 0.7×	35 0.3×	67 0.7×	63 0.8×	65 0.9×	26	431
Mojtaba Shahin Iran	13	155 0.8×	27 0.2×	68 0.7×	90 1.2×	145 1.9×	31	421
Paraskevi Mantzana Greece	9	88 0.5×	59 0.5×	111 1.1×	42 0.5×	164 2.2×	22	357

Countries citing papers authored by Jennifer I. Smart

Since Specialization

Citations

This map shows the geographic impact of Jennifer I. Smart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer I. Smart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer I. Smart more than expected).

Fields of papers citing papers by Jennifer I. Smart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer I. Smart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer I. Smart. The network helps show where Jennifer I. Smart may publish in the future.

Co-authorship network of co-authors of Jennifer I. Smart

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer I. Smart. A scholar is included among the top collaborators of Jennifer I. Smart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer I. Smart. Jennifer I. Smart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sader, Hélio S., et al.. (2025). Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022. Antimicrobial Agents and Chemotherapy. 69(2). e0140224–e0140224. 1 indexed citations

Shorr, Andrew F., et al.. (2025). Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance. PLoS ONE. 20(6). e0326758–e0326758.

Hahn, Mark M., Michael S. Anderson, Jennifer I. Smart, et al.. (2023). Ceftobiprole Medocaril Is an Effective Post-Exposure Treatment in the Fischer 344 Rat Model of Pneumonic Tularemia. Antibiotics. 12(8). 1337–1337. 3 indexed citations

Bhavnani, Sujata M., Jeffrey Hammel, Jennifer I. Smart, et al.. (2023). 2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB). Open Forum Infectious Diseases. 10(Supplement_2).

Duncan, Leonard R, Kamal Hamed, Jennifer I. Smart, et al.. (2022). Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020. Diagnostic Microbiology and Infectious Disease. 103(3). 115713–115713. 3 indexed citations

Holland, Thomas L, Sara E. Cosgrove, Sarah B. Doernberg, et al.. (2022). LB2302. Ceftobiprole Compared to Daptomycin With or Without Optional Aztreonam for the Treatment of Complicated Staphylococcus aureus (SAB): Results of a Phase 3, Randomized, Double-Blind Trial (ERADICATE). Open Forum Infectious Diseases. 9(Supplement_2). 3 indexed citations

Flamm, Robert K., Leonard R Duncan, Kamal Hamed, et al.. (2020). Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018. Antimicrobial Agents and Chemotherapy. 64(6). 17 indexed citations

Pfaller, Michael A., Robert K. Flamm, Leonard R Duncan, et al.. (2019). Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016–2017). Diagnostic Microbiology and Infectious Disease. 94(3). 304–313. 22 indexed citations

Henriksen, Anne Santerre, Jennifer I. Smart, & Kamal Hamed. (2018). Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015. European Journal of Clinical Microbiology & Infectious Diseases. 37(9). 1653–1659. 11 indexed citations

10.

Henriksen, Anne Santerre, Jennifer I. Smart, & Kamal Hamed. (2018). Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015. Infection and Drug Resistance. Volume 11. 1309–1320. 9 indexed citations

11.

Pfaller, Michael A., Hélio S. Sader, Robert K. Flamm, et al.. (2017). In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions. Microbial Drug Resistance. 23(6). 718–726. 8 indexed citations

12.

Jones, Ronald N., Robert K. Flamm, Mariana Castanheira, et al.. (2017). Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. Diagnostic Microbiology and Infectious Disease. 88(2). 184–187. 12 indexed citations

13.

Flamm, Robert K., Leonard R Duncan, Dee Shortridge, et al.. (2017). Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016). Open Forum Infectious Diseases. 4(suppl_1). S368–S368. 3 indexed citations

14.

Mendes, Rodrigo E., Hélio S. Sader, Jennifer I. Smart, Mariana Castanheira, & Robert K. Flamm. (2017). Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014). European Journal of Clinical Microbiology & Infectious Diseases. 36(6). 1013–1017. 10 indexed citations

15.

Shinabarger, Dean L., et al.. (2017). Evaluation of the bactericidal activity of Telavancin against Staphylococcus aureus using revised testing guidelines. Diagnostic Microbiology and Infectious Disease. 89(1). 83–85. 4 indexed citations

16.

Duncan, Leonard R, Hélio S. Sader, Jennifer I. Smart, Robert K. Flamm, & Rodrigo E. Mendes. (2017). Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014). Journal of Global Antimicrobial Resistance. 10. 271–276. 16 indexed citations

17.

Duncan, Leonard R, Jennifer I. Smart, Robert K. Flamm, et al.. (2016). Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013–2014). Diagnostic Microbiology and Infectious Disease. 86(3). 300–302. 6 indexed citations

18.

Smart, Jennifer I., G. Ralph Corey, Martín E. Stryjewski, Whedy Wang, & Steven L. Barriere. (2016). Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates. Infectious Diseases and Therapy. 5(4). 535–544. 4 indexed citations

19.

Smart, Jennifer I., G. Ralph Corey, Martín E. Stryjewski, Whedy Wang, & Steven L. Barriere. (2016). Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates. Diagnostic Microbiology and Infectious Disease. 87(3). 268–271. 4 indexed citations

20.

Xayarath, Bobbi, Karl Volz, Jennifer I. Smart, & Nancy E. Freitag. (2011). Probing the Role of Protein Surface Charge in the Activation of PrfA, the Central Regulator of Listeria monocytogenes Pathogenesis. PLoS ONE. 6(8). e23502–e23502. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact